Skip to main content

Year: 2019

Evolving Gold Announces Closing of Financing

VANCOUVER, British Columbia, Dec. 02, 2019 (GLOBE NEWSWIRE) — Evolving Gold Corp. (CSE: EVG) (FSE: EV7) (OTCB: EVOGF) (the “Company” or “EVG”) announces that in October 2019 it borrowed the sum of $60,000 from JMM Trading LP (the “Lender”) for purposes of financing its audited financial statements for the fiscal year ended March 31st, 2019 and the costs associated with obtaining revocation orders to the previously outstanding cease trade orders issued by the BCSC and OSC.The loan is unsecured, bears interest at the rate of 10% per annum, and matures in 12 months.The Company has now agreed that:the loan will be convertible to common shares of the Company (“Shares”) at the lesser of $0.075 per Share or such price the Company has then most recently issued Shares on a private or public basis (subject to a minimum $0.05 per Share);the...

Continue reading

BOK Financial Recognized Among the World’s Best Employers by Forbes

TULSA, Okla., Dec. 02, 2019 (GLOBE NEWSWIRE) — BOK Financial, one of the nation’s largest regional financial services companies, was recently recognized on Forbes’ list of the World’s Best Employers. The list of 500 employers is developed from the world’s 2,000 largest public companies with input from a global poll of employees.Forbes partnered with Statistica to analyze 1.4 million recommendations sourced from a global poll and regional surveys. Survey respondents were asked to rate their own employer and the likelihood that they would recommend this employer to a friend or family member. They also rated other employers they admired.More than 50 regional banks made the list of 500; BOK Financial was third-highest among American regional financial services companies at an overall ranking of No. 319.“This recognition reinforces our...

Continue reading

ADLPartner : Déclaration des transactions sur actions propres réalisées du 25 au 29 novembre 2019

ADLPartnerSociété anonyme à directoire et conseil de surveillance au capital de 6 478 836 euros3, avenue de Chartres 60500 – CHANTILLY393 376 801 R.C.S. CompiègneDéclaration des transactions sur actions propres réalisées du 25 au 29 novembre 2019Présentation agrégée par jour et par marchéLe reporting détaillé est disponible sur le site internet du Groupe ADLPartner : www.adlpartner.com dans l’espace Actualités investisseurs/ Informations réglementées.Relations Investisseurs & Informations financièresTel : +33 1 41 58 72 03 – Courriel : relations.investisseurs@adlpartner.frADLPartner est cotée sur Euronext Paris – Compartiment CCodes ISIN : FR0000062978-ALP – Bloomberg : ALP FP – Reuters : ALDP.PAwww.adlpartner.comPièce jointeADLPartner_rachats_actions_02122019

Continue reading

Herantis Pharma Plc’s directed share issue is oversubscribed multiple times and completed as planned

Herantis Pharma Plc’s directed share issue is oversubscribed multiple times and completed as plannedHerantis Pharma PlcCompany release 2 December 2019 at 8:00 pmTHE INFORMATION CONTAINED IN THIS RELEASE IS NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA OR THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.Herantis Pharma Plc’s (“Herantis” or the “Company“) Offering (as defined below) has ended and the board of directors of the Company has today resolved on the completion of the Offering.In the Offering, the Company issues a total of 618,018 new shares (the “Offer Shares“) in a directed share issue (the “Offering“), provided that the Offer Shares...

Continue reading

Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellusti

Herantis Pharma Oyj:n suunnattu osakeanti on ylimerkitty moninkertaisesti ja toteutetaan suunnitellustiHerantis Pharma OyjYhtiötiedote 2.12.2019 kello 20:00TÄMÄN TIEDOTTEEN SISÄLTÄMÄ TIETO EI OLE TARKOITETTU JULKISTETTAVAKSI TAI LEVITETTÄVÄKSI SUORAAN TAI VÄLILLISESTI AUSTRALIASSA, ETELÄ-AFRIKASSA, HONGKONGISSA, JAPANISSA, KANADASSA, SINGAPORESSA TAI YHDYSVALLOISSA TAI MISSÄÄN MUUSSA VALTIOSSA, JOSSA LEVITTÄMINEN TAI JULKAISEMINEN OLISI LAINVAISTAISTA.Herantis Pharma Oyj:n (“Herantis” tai “Yhtiö“) Osakeanti (määritelty jäljempänä) on päättynyt ja Yhtiön hallitus on tänään päättänyt Osakeannin toteuttamisesta.Osakeannissa Yhtiö laskee liikkeeseen yhteensä 618.018 Yhtiön uutta osaketta (“Tarjottavat Osakkeet“) suunnatulla osakeannilla (“Osakeanti“) edellyttäen, että kaikki merkityt Tarjottavat...

Continue reading

Consolidated Communications to Present at Wells Fargo TMT Summit

MATTOON, Ill., Dec. 02, 2019 (GLOBE NEWSWIRE) — Consolidated Communications Holdings, Inc. (Nasdaq: CNSL) announced Bob Udell, president and chief executive officer of Consolidated Communications, will present at the Wells Fargo TMT Summit in Las Vegas on Wednesday, Dec. 4 at 3:20 p.m. PT.  The event will be webcast live and available on-demand on the Investor Relations section of the Consolidated Communications website.                                                                                                                                               About Consolidated Communications Consolidated Communications Holdings, Inc. (NASDAQ: CNSL) is a leading broadband and business communications provider serving consumers, businesses, and wireless and wireline carriers across rural and metro communities and a 23-state service...

Continue reading

GUERBET : Déclaration des opérations sur actions propres (agrégée)

La présentation détaillée transaction par transaction est disponible via le lien suivant : https://www.guerbet.com/media/f1jlhfcg/cp-rachat-actions-hebdomadaire-détaillée-02122019.pdfPionnier dans le domaine des produits de contraste avec plus de 90 années d’expérience, Guerbet est un des leaders de l’imagerie médicale au niveau mondial. Il dispose d’une gamme complète de produits pharmaceutiques, de dispositifs médicaux et de services pour l’imagerie diagnostique et interventionnelle afin d’améliorer la prise en charge thérapeutique des patients. Avec 8 % de ses ventes consacrées à la R&D et plus de 200 collaborateurs répartis dans 4 centres en France, en Israël et aux États-Unis, Guerbet mobilise d’importantes ressources pour la recherche et l’innovation. Guerbet (GBT) est coté au compartiment B d’Euronext Paris et a réalisé en 2018...

Continue reading

Aslan Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

SINGAPORE, Dec. 02, 2019 (GLOBE NEWSWIRE) — ASLAN Pharmaceuticals (Nasdaq: ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today announced that it has commenced an underwritten public offering of its American Depositary Shares (“ADSs”) representing ordinary shares. In addition, ASLAN expects to grant the underwriter an option, exercisable at any time through and until one day before the potential closing date of this offering, to purchase up to an additional 15% of the ADSs being offered on the same terms and conditions. All ADSs to be sold in the offering will be offered by ASLAN. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.ASLAN intends to use the net proceeds...

Continue reading

TC Energy provides dividend rate notice for Series 1 and 2 preferred shares

CALGARY, Alberta, Dec. 02, 2019 (GLOBE NEWSWIRE) — News Release — TC Energy Corporation (TSX:TRP) (NYSE:TRP) (TC Energy) announced today that it has notified the registered shareholders of the applicable dividend rates for its Cumulative Redeemable First Preferred Shares, Series 1 (Series 1 Shares) and its Cumulative Redeemable First Preferred Shares, Series 2 (Series 2 Shares).As previously announced in the Company’s news release dated November 21, 2019, holders of the Series 1 Shares have the right on December 31, 2019 to convert, on a one-for-one basis, any or all of their Series 1 Shares into Series 2 Shares and receive a floating rate quarterly dividend, or retain any or all of their Series 1 Shares and receive a new fixed rate quarterly dividend.Holders of the Series 2 Shares have the right on December 31, 2019 to convert,...

Continue reading

Ymagis S.A announces unanimous financial restructuring agreement with its bondholders and bank creditors

Press releaseParis (France) – December 2, 2019, 6:15 pmYmagis S.A announces unanimous financial restructuring agreement with its bondholders and bank creditorsFinancial debt write-off of between €13.9m and €16.2mIssuance of €9.2m of convertible bonds based on ordinary shares with an implied price of €3.00 per ordinary shareRescheduling of €26.8m of residual debt over seven yearsYmagis presents its strategic plan and details of its financial restructuring plan in an appendix on its website www.ymagis.comYmagis Group (FR0011471291, MAGIS, PEA-PME), the European specialist in digital technologies for the cinema industry, today announced that an agreement has been reached with all its bondholders and bank creditors for a financial restructuring plan (the “Restructuring Agreement”) that meets the three objectives set by the Company during...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.